Exascale Labs Holdings Inc. filed a Form S-1 registration statement with the SEC on October 30, 2026, covering the resale of up to 12,350,000 shares of Class A Common Stock by selling securityholders following the company's August 2026 business combination.

Key Highlights

  • Shares registered: Up to 12,250,000 shares of Class A Common Stock plus up to 100,000 shares issuable upon exercise of warrants, for a total of up to 12,350,000 shares.
  • Business combination date: The company consummated its business combination on August 27, 2026, involving BCAR, Merger Sub, and Legacy Exascale Inc.
  • No proceeds to the company: According to the filing, Exascale Labs will not receive any cash proceeds from sales of Class A Common Stock by the selling securityholders, though it will receive net proceeds from any warrants exercised for cash.
  • Share breakdown: The registered shares consist of 10,933,369 shares distributed from sponsor MFH 1, LLC; 316,631 shares issued to John Darwin; 1,000,000 shares held by David Boral; and 100,000 shares underlying warrants held by the sponsor.
  • Stock price at filing: The last reported sale price of Class A Common Stock on the Nasdaq Global Market on October 29, 2026 was $3.15 per share.
  • Company classification: The registrant identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company.

Exascale Labs Registers Selling Securityholder Shares Following SPAC Merger

Exascale Labs Holdings Inc., trading on the Nasdaq Global Market under the symbol XLAB (NASDAQ:XLAB), filed a preliminary Form S-1 registration statement on October 30, 2026, to register the resale of shares held by certain securityholders who received their positions through the company's August 2026 business combination with D. Boral ARC Acquisition I Corp. ("BCAR"), a special purpose acquisition company. The filing states that the business combination closed on August 27, 2026, and involved BCAR reincorporating in Delaware before Merger Sub merged with and into Legacy Exascale Inc., which became a wholly owned subsidiary of the renamed holding company.

According to the filing, the 12,350,000 shares being registered for resale are broken into four categories. The largest portion, 10,933,369 shares, was distributed to certain selling securityholders from sponsor MFH 1, LLC following the sponsor's receipt of those shares in exchange for BCAR Class B ordinary shares. An additional 316,631 shares were issued to John Darwin, described as BCAR's former Chief Financial Officer and manager of the Sponsor. David Boral holds 1,000,000 shares issued to D. Boral Capital LLC as compensation in connection with BCAR's IPO, and 100,000 shares underlie warrants issued to the Sponsor from a private placement concurrent with that IPO.

The filing notes that the securities registered for resale "represent a substantial percentage of our total outstanding Class A Common Stock as of the date of this prospectus," and states that potential sale of all such securities "could result in a significant decline in the public trading" price. The company disclosed it will pay expenses associated with the registration, excluding underwriting discounts, commissions, and expenses incurred by the selling securityholders themselves. The registration is being conducted on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933.

What Was Disclosed

Exascale Labs Holdings Inc. filed an S-1 on October 30, 2026, registering up to 12,350,000 Class A Common Stock shares for resale by selling securityholders who received their shares through the August 27, 2026 business combination with BCAR. The company will not receive proceeds from these resales.